- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
- The FDA has ruled on copycat drugs produced in China, while Novo Nordisk navigates price reduction demands from Trump and leadership changes.
- Trump administration announced FDA coverage changes regarding Chinese suppliers who are not registered.
The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
2 reports, 0 independent
Updated Jun 25
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Trump administration announced FDA coverage changes regarding Chinese suppliers who are not registered.Also in this story
- The Trump administration is leading to FDA job cuts, while Elon Musk spearheaded the Department of Government Efficiency, and China has surpassed the US in clinical trial volume.
- The FTC is scrutinizing companies for Chinese sourcing claims amid concerns over unlawful Chinese vapes flooding the US.
The entities involved
- FDA
-
Merck KGaA
German multinational science and technology company
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
Related events
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- FDA clearance enables market entry into the U.S. for an unnamed company, which is also navigating the long-term regulatory process in Japan.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet